Actively Recruiting
Study of Budesonide and Ambrisentan Combination Treatment for Adults with IgA Nephropathy and Kidney Disease Risk
Led by The First Hospital of Jilin University · Updated on 2025-09-15
129
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the use of Budesonide combined with Ambrisentan for treating patients with IgA nephropathy who have a risk of progressing to end-stage kidney disease ESKD. This prospective, single-arm clinical trial aims to observe the effects of this combination on reducing urinary protein levels and slowing the decline of kidney function, as well as changes in serum Gd-IgA1 levels. The study is planned to include 129 patients diagnosed with primary IgA nephropathy. Participants who meet the screening criteria will receive Budesonide at a dose of 16 mg per day and Ambrisentan at 5 mg per day, both taken orally for 36 weeks. The study includes a screening period completed within 30 days before treatment begins and a total of six visits throughout the study. After the treatment period, data from all enrolled patients will be analyzed, and if results are promising, further randomized controlled trials may be conducted. During the study, participants will undergo multiple visits for medical history review, medication monitoring, and examination results collection to ensure eligibility and safety. Researchers will measure changes in 24-hour urinary protein, estimated glomerular filtration rate eGFR, and serum levels of IgA, IgG, IgM, and Gd-IgA1 from enrollment through the 36-week treatment. The trial also monitors the annualized eGFR slope to assess kidney function progression over the study period.
CONDITIONS
Brief Title
Nefecon and Ambrisentan in IgA Nephropathy
Research Team
W
Weixia Sun
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here